Jaguar Health在宠物连通会议上寻求新狗腹泻药物NP300的合作伙伴。 Jaguar Health seeks partner for new dog diarrhea drug, NP300, at Pet Connect conference.

Jaguar Health寻求一个伙伴来研制和销售NP300,这是一种治疗狗一般腹泻的新药物。 Jaguar Health seeks a partner to develop and commercialize NP300, a new drug for treating general diarrhea in dogs. 目前,林业发展局没有为此问题批准的药物,每年大约有600万只狗受到影响。 Currently, there are no FDA-approved drugs for this issue, which affects around 6 million dogs annually. NP300,与Jaguar批准用于化疗引起的腹泻的Canalevia-CA1药物类似,目的是填补这一市场缺口。 NP300, similar to Jaguar's approved drug Canalevia®-CA1 for chemotherapy-induced diarrhea, aims to fill this market gap. 该公司计划在Pet Connect会议上寻找一个伙伴,资助和执行NP300的发展。 The company plans to find a partner at the Pet Connect conference to fund and execute NP300's development.